智通财经APP获悉，宜明昂科-B(01541)盘中涨超5%，截至发稿，涨3.19%，报5.18港元，成交额5266.84万港元。
消息面上，宜明昂科此前发布公告称，向张江集团出售位于上海市浦东新区康桥工业园区、土地面积约28763平方米的工业土地，现金对价最高9819万元人民币。此外，宜明昂科近期完成配售事宜，净筹约2.3亿港元，其中70%用于在中国进行包括替达派西普与替雷利珠单抗联合疗法的关键性临床研究提供资金；及约30%作一般企业用途。
太平洋证券指出，公司CD47/SIRPα融合蛋白IMM01联合替雷利珠单抗治疗R/R cHL、以及IMM01联合阿扎胞苷治疗1L CMML的III期临床正在积极入组中，有望验证CD47/SIRPα靶点成药性。此外，公司CD47/CD20双抗IMM0306与来那度胺联用，治疗B-NHL的Ib/IIa期临床正在进行中，以及IMM0306用于SLE治疗的Ib/II期临床也在积极入组中。此外，公司PD-L1/VEGF双抗 IMM2510目前在NSCLC、TNBC和R/R STS三个适应症上开展早期临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.